Abstracts tagged "giant cell arteritis"

Abstract Number: 793 • 2017 ACR/ARHP Annual Meeting
Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be
Ignacio Castaño¹, Irene Monjo², Alejandro Balsa³, Diana Peiteado², Sara García-Carazo⁴ and Eugenio De Miguel¹, ¹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²Rheumatology, Hospital Universitario La Paz, MADRID, Spain, ³Rheumatology, Hospital La Paz-IdiPAZ, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: The high-dose glucocorticoids (GCs) are the mainstay of treatment in Giant Cell Arteritis (GCA). Patients treated with greater GC dosages are at the greatest…
Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Takahiko Sugihara¹, Hitoshi Hasegawa², Haruhito Uchida³, Hajime Yoshifuji⁴, Yoshikazu Nakaoka⁵, Yoshiko Watanabe⁶, Eisuke Amiya⁷, Masanori Konishi⁸, Yasuhiro Katsumata⁹, Yoshinori Komagata¹⁰, Taio Naniwa^11,12, Takahiro Okazaki¹³, Yoshiya Tanaka¹⁴, Tsutomu Takeuchi¹⁵, Masayoshi Harigai¹⁶, Yoshihiro Arimura¹⁷ and Mitsuaki Isobe^8,18, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁷Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰First Dept. of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹¹Division of Rheumatology, Dept of Internal Medicine,, Nagoya City University Hospital, Nagoya, Japan, ¹²Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…
Abstract Number: 796 • 2017 ACR/ARHP Annual Meeting
Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases
Laure Delaval^1,2, Aurélie Daumas³, Maxime Samson⁴, Mikael Ebbo⁵, Hubert de Boysson⁶, Eric Liozon⁷, Henry Dupuy⁸, Alexis Regent⁹, Mathieu Puyade¹⁰, Daniel Blockmans¹¹, Estibaliz Lazaro¹², Ygal Benhamou¹³, Karim Sacre¹⁴, Alice Bérezné¹⁵, Loïc Guillevin^2,9,16 and Benjamin Terrier^17,18,19, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Marseille, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵internal medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Paris, France, ⁶Department of Internal Medicine, Caen University Hospital, Caen, France, ⁷Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁰Department of Internal Medicine, University Hospital of Poitiers, Poitiers, France, ¹¹General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ¹²Department of Internal Medecine and Clinical Immunology, Bordeaux University Hospital, Pessac, France, ¹³Department of internal medicine, University Hospital of Rouen, Rouen, France, ¹⁴Department of Internal Medicine, Bichat Hospital, Paris, France, ¹⁵Department of internal medicine, CHR Annecy-Genevois, Metz-Tessy, France, ¹⁶French Vasculitis Study Group (FVSG), Paris, France, ¹⁷Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁸Internal Medicine, Cochin University Hospital, Paris, France, ¹⁹French Vasculitis Study Group (FVSG), paris, France
Background/Purpose: Primary large-vessel vasculitis (LVV) include giant cell arteritis (GCA) and Takayasu arteritis (TA). Age at onset is commonly used to distinguish GCA and TA.…
Abstract Number: 884 • 2016 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine Sreih², Gunnar Tomasson³, David Cuthbertson⁴, Simon Carette⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux¹³, Philip Seo¹⁴, Kenneth J. Warrington¹⁵, Steven R. Ytterberg¹⁶ and Peter A. Merkel¹⁷, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁴Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁵Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁶Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: To evaluate health-related quality of life (HRQoL) in a large cohort of patients with giant cell arteritis (GCA) as measured by the 36-item…
Abstract Number: 3197 • 2016 ACR/ARHP Annual Meeting
Ultrasound Definitions for Cranial and Large Vessel Giant Cell Arteritis: Results of a Reliability Exercise on Images and Videos of the Omeract Ultrasound Large Vessel Vasculitis Task Force
Stavros Chrysidis¹, Christina Duftner², Christian Dejaco³, Cristina Ponte⁴, Annamaria Iagnocco⁵, Bhaskar Dasgupta⁶, Maria Antonietta D'Agostino⁷, Eugenio De Miguel⁸, Ulrich Fredberg⁹, Wolfgang Hartung¹⁰, Alojzija Hocevar¹¹, Tanaz A. Kermani¹², Matthew J. Koster¹³, Tove Lorenzen¹⁴, Pierluigi Macchioni¹⁵, Marcin Milchert¹⁶, Naina Rastalsky¹⁷, Chetan Mukhtyar¹⁸, Valentin S. Schaefer¹⁹, Kenneth J. Warrington²⁰, Lene Terslev²¹, George A. W. Bruyn²², Petra Hanova²³, Uffe Møller Døhn²⁴, Esperanza Naredo²⁵, Carlo Alberto Scirè²⁶, Greta Carrara²⁷, Sofia Ramiro²⁸, Andreas P Diamantopoulos²⁹ and Wolfgang A. Schmidt¹⁹, ¹Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ²Medical University Innsbruck, Innsbruck, Austria, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Rheumatology and Metabolic Bone Diseases Department, Rheumatology Research Unit - IMM, Lisbon Academic Medical Centre, Lisbon, Portugal, ⁵Sapienza Università Di Roma,, Roma, Italy, ⁶Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁸Hospital Universitario La Paz, Madrid, Spain, ⁹Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, ¹⁰Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹²Rheumatology, University of California Los Angeles, Santa Monica, CA, ¹³Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ¹⁴Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ¹⁵Arcispedale Santa Maria Nuova, Reggio Emilia,, Reggio Emilia, Italy, ¹⁶Pomeranian Medical University, Szczecin,, Szczecin, Poland, ¹⁷St. Elizabeth's Medical Center, Boston, MA, Boston, MA, ¹⁸Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹⁹Immanuel Krankenhaus Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, Germany, ²⁰Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²²Rheumatology, MC Groep, Loenga, Netherlands, ²³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ²⁵Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain, ²⁶Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ²⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ²⁸Leiden University Medical Center, Leiden, Netherlands, ²⁹Rheumatology, Haugesund Sanitetsforenings Revmatismesykehus, Haugesund, Norway
Background/Purpose: By a Delphi process, the OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal temporal arteries…
Abstract Number: 894 • 2016 ACR/ARHP Annual Meeting
Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?
Alexis Jones¹, Joe Li² and Charles Li³, ¹Rheumatology, University College London, LONDON, United Kingdom, ²Rheumatology, Royal Surrey County Hospital, Guildford, United Kingdom, ³Royal Surrey County Hospital, Guildford, Great Britain
Background/Purpose: The initial suspicion of Giant cell arteritis (GCA) is often made in the setting of primary care or casualty by a non-rheumatologist. Whilst temporal…
Abstract Number: 897 • 2016 ACR/ARHP Annual Meeting
Discordance Rates of Bilateral Temporal Artery Biopsies: A Retrospective Analysis
Jon Golenbiewski¹ and Alexandra Halalau², ¹Internal Medicine, Beaumont Health System, Oakland University William Beaumont School of Medicine, Royal Oak, MI, ²Beaumont Health System, Oakland University William Beaumont School of Medicine, Royal Oak, MI
Background/Purpose: Previous retrospective studies have suggested that simultaneous bilateral temporal artery biopsy (TAB) may lead to increased detection rates of giant cell arteritis (GCA). The term…
Abstract Number: 898 • 2016 ACR/ARHP Annual Meeting
Treatment and Outcome of Patients with a Diagnosis of Healed Arteritis on Temporal Artery Biopsy
Daniel Jo¹, Melissa Fazzari², Donald Brand³, Steven E. Carsons⁴ and Elise Belilos¹, ¹Rheumatology, Winthrop University Hospital, Mineola, NY, ²Biostatistics, Winthrop University Hospital, Mineola, NY, ³Office of Health Outcomes Research, Winthrop University Hospital, Mineola, NY, ⁴Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY
Background/Purpose: Temporal artery biopsy (TAB) is the gold standard for the diagnosis of Giant Cell Arteritis (GCA), yet is limited by the presence of skip…
Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Martin Aringer³, Guido Hoese⁴, Wolfgang Ochs⁵, Katja Thiele¹ and Angela Zink^1,2, ¹Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ⁴Rheumatologische Fachpraxis Stadthagen, Stadthagen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany
Background/Purpose: Methods: Conclusion:
Abstract Number: 900 • 2016 ACR/ARHP Annual Meeting
The Phenotype of Macrophages in the Inflamed Vascular Wall of Giant Cell Arteritis Resembles the Phenotype of Non-Classical Monocytes
Yannick van Sleen, Qi Wang, Wayel H. Abdulahad, Arjan Diepstra, Annemieke M.H. Boots and Elisabeth Brouwer, Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Macrophages are critical tissue destructive cells in the immunopathology of patients with giant cell arteritis (GCA). Macrophage precursors, monocytes, can be subclassified in three…
Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Luis Rodriguez Rodriguez¹, Leticia Leon², Inmaculada Morado¹, Zulema Rosales Rosado², Cristina Vadillo Font¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, Benjamín Fernández-Gutiérrez³, Juan A Jover Jover² and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…
Abstract Number: 856 • 2016 ACR/ARHP Annual Meeting
Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy
Lindsay Lally¹, Navneet Narula², Nicola Goodfellow³, Raashid Luqmani⁴ and Robert F. Spiera⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Pathology, Weill Cornell Medical College, New York, NY, ³Oxford, Oxofrd, United Kingdom, ⁴Oxford, Oxford, United Kingdom, ⁵Hospital for Special Surgery, Cornell, New York, NY
Background/Purpose: Aberrant rho-kinase (ROCK) activity is implicated in pathogenesis of several vascular and immunologic disorders. We previously demonstrated evidence of increased ROCK activity in histopathologically…
Abstract Number: 909 • 2016 ACR/ARHP Annual Meeting
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Bhaskar Dasgupta¹, Asad Khan¹, Dimos Merinopoulos¹, Siwalik Banerjee², Dawn Gayford³, Philip Stapleton¹, Faidra Laskou¹ and Gianina Statache¹, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Wescliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital NHS Foundation Trust, westcliff-on-Sea, United Kingdom
Background/Purpose: It is reported that 15-25% patients with GCA present with visual complications. Sight loss (SL) in the elderly is associated with considerable morbidity. There…
Abstract Number: 857 • 2016 ACR/ARHP Annual Meeting
Ultrasound Cut-Off Values for Intima-Media Thickness of Temporal, Facial and Axillary Arteries in Giant Cell Arteritis
Valentin S. Schäfer¹, Aaron Juche², Sofia Ramiro³, Andreas Krause² and Wolfgang A. Schmidt⁴, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Abstract Background/Purpose: Ultrasound (US) is increasingly used in the diagnosis of giant cell arteritis (GCA). US findings mainly rely on morphology (“halo-sign” and “compression sign”).…
Abstract Number: 977 • 2016 ACR/ARHP Annual Meeting
Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study
Maxime Samson¹, Hervé Devilliers², Kim Heang Ly³, Francois Maurier⁴, Boris Bienvenu⁵, Benjamin Terrier⁶, Pierre Charles⁷, Jean-François Besancenot², Anne-Laure Fauchais⁸, Christine Binquet⁹, Sylvain Audia¹⁰ and Bernard Bonnotte¹, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Internal Medicine, University Hospital of Limoges, Limoges, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Caen University Hospital, Caen, France, ⁶Internal Medicine, Cochin University Hospital, Paris, France, ⁷Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁸Department of Internal Medicine, CHU de Limoges, Limoges, France, ⁹INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis usually treated with glucocorticoids (GC). GC are effective but responsible for substantial morbidity and mortality. Tocilizumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].